CANFNYSEPharmaceutical PreparationsFiscal year ends December 31
Can-Fite BioPharma Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$1.89+0.13 (+7.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Can-Fite BioPharma statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Can-Fite BioPharma | Industry median |
|---|---|---|
| Market Cap | $2.47M | $166.30M |
| Enterprise Value | -$3.05M | $87.12M |
| PS Ratio | 6.11 | 3.60 |
| PB Ratio | 0.44 | 2.03 |
| P/TBV Ratio | 0.44 | 2.31 |
Enterprise value
| Measure | Can-Fite BioPharma | Industry median |
|---|---|---|
| EV / Sales | -7.54 | 2.43 |
Income (trailing twelve months)
| Measure | Can-Fite BioPharma | Industry median |
|---|---|---|
| Revenue | $405.00K | $57.94M |
| Operating Income | -$9.95M | -$21.49M |
| Pretax Income | -$9.83M | -$14.72M |
| Net Income | -$9.83M | -$22.46M |
| EBITDA | -$9.93M | -$17.14M |
| EPS (Diluted) | -$5.97 | -$0.83 |
Margins
| Measure | Can-Fite BioPharma | Industry median |
|---|---|---|
| Operating Margin | -2456.8% | -44.5% |
| Pretax Margin | -2426.7% | -13.0% |
| Profit Margin | -2426.7% | -39.2% |
| EBITDA Margin | -2450.9% | -31.3% |
| FCF Margin | -2210.1% | -8.85% |
Returns
| Measure | Can-Fite BioPharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -178.2% | -53.2% |
| Return on Assets (ROA) | -105.5% | -41.0% |
| Return on Capital Employed (ROCE) | -146.7% | -38.0% |
Growth
| Measure | Can-Fite BioPharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -39.9% | 6.01% |
| Revenue Growth (3Y CAGR) | -20.6% | 2.25% |
| Revenue Growth (5Y CAGR) | -11.9% | 6.42% |
Balance sheet
| Measure | Can-Fite BioPharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $5.53M | $62.64M |
| Net Cash (Debt) | $5.53M | $15.77M |
| Net Cash Per Share | $2.11 | $0.66 |
| Equity (Book Value) | $5.59M | $48.61M |
| Book Value Per Share | $2.14 | $1.36 |
| Tangible Book Value | $5.59M | $23.01M |
| Working Capital | $6.71M | $75.09M |
Financial position
| Measure | Can-Fite BioPharma | Industry median |
|---|---|---|
| Current Ratio | 3.46 | 3.30 |
| Quick Ratio | 2.02 | 2.39 |
| Interest Coverage | -35.04 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Can-Fite BioPharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$8.95M | -$12.39M |
| Capital Expenditures | -$2.00K | -$1.07M |
| Free Cash Flow | -$8.95M | -$20.34M |
| FCF Per Share | -$3.42 | -$0.42 |
Efficiency
| Measure | Can-Fite BioPharma | Industry median |
|---|---|---|
| Asset Turnover | 0.04 | 0.38 |
| Revenue Per Employee | $81.00K | $398.96K |
| Profits Per Employee | -$1.97M | -$705.27K |
| Employee Count | 5 | 74 |
Dividends and yields
| Measure | Can-Fite BioPharma | Industry median |
|---|---|---|
| Earnings Yield | -397.2% | -22.8% |
| FCF Yield | -361.7% | -9.02% |
| Buyback Yield | -118.5% | -0.73% |
| Shareholder Yield | -118.5% | 0.00% |
Shares
| Measure | Can-Fite BioPharma | Industry median |
|---|---|---|
| Shares Outstanding | 2,618,430 | 58,139,000 |
| Shares Change (YoY) | 127.0% | 11.1% |
| Float | 2,618,330 | 49,154,900 |
| Shares Held by Insiders | 0.00% | 11.6% |
| Shares Held by Institutions | 1.92% | 59.4% |
Scores
| Measure | Can-Fite BioPharma | Industry median |
|---|---|---|
| Altman Z-Score | -28.11 | -0.27 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Can-Fite BioPharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.